Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd ADR (NY: RDY )

72.09 +0.53 (+0.74%)
Official Closing Price Updated: 7:00 PM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 132,867
Open 71.85
Bid (Size) 71.78 (5)
Ask (Size) 73.57 (1)
Prev. Close 71.56
Today's Range 71.78 - 72.37
52wk Range 61.25 - 77.72
Shares Outstanding 166,301,231
Dividend Yield 1.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
From Aurigene Pharmaceutical Services Ltd.
Via Business Wire
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections. 
Via Investor's Business Daily

Performance

YTD
+1.78%
+1.78%
1 Month
+1.62%
+1.62%
3 Month
-1.80%
-1.80%
6 Month
+7.15%
+7.15%
1 Year
+17.33%
+17.33%

More News

Read More
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
Dr Reddy's Laboratories: Q3 Earnings Insights
Via Benzinga
Is NYSE:RDY suited for quality investing?
Via Chartmill
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Alvotech
Via GlobeNewswire
Should you consider NYSE:RDY for quality investing?
Via Chartmill
Chart Of The Day: What's Cooking At Dr. Reddy's Lab
Via Talk Markets
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024
Via InvestorPlace
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Dr. Reddy’s Q3 & 9M FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
2 overlooked stocks that crushed earnings but traded lower
Via MarketBeat
Exposures Product Safety
Dr. Reddy’s Q2 FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities.
Via Chartmill
Top 5 Health Care Stocks That May Fall Off A Cliff
Via Benzinga
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
Dr. Reddy’s Q1 FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.